CJC-1295: Long-Acting GHRH Analogue — Clinical Profile and How It Differs from Mod GRF

CJC-1295 is a modified GHRH analogue designed for extended duration of action. Its drug affinity complex (DAC) modification allows it to bind albumin in the bloodstream, extending its half-life from minutes to several days and creating a sustained elevation in GH pulsatility.

By UAE Peptide Clinic Research Desk

CJC-1295 is a modified GHRH analogue designed for extended duration of action. Its most distinctive feature is a drug affinity complex (DAC) modification — a chemical structure that allows the peptide to bind covalently to albumin in the bloodstream, dramatically extending its half-life from minutes to several days. This extended presence creates a sustained elevation in baseline GHRH signalling, shifting the entire GH pulse pattern upward.

CJC-1295 vs. Modified GRF 1-29

The name CJC-1295 is sometimes used interchangeably with Modified GRF 1-29 (Mod GRF), but they are different compounds. Mod GRF 1-29 is CJC-1295 without the DAC modification — it has a short half-life similar to native GHRH and produces an acute GH pulse when injected. CJC-1295 with DAC produces a prolonged GH elevation. Clinically, the choice depends on the protocol goal: acute pulse amplitude (Mod GRF) versus sustained baseline elevation (CJC-1295 DAC).

Clinical Applications

CJC-1295 is most commonly prescribed in combination with Ipamorelin — the sustained GHRH effect from CJC-1295 combines with the clean ghrelin-receptor stimulus of Ipamorelin to produce a protocol that is effective, flexible in injection timing, and well-tolerated. It is appropriate for patients seeking the full spectrum of GH-axis restoration: body composition, sleep quality, recovery, and skin health.

• DAC modification extends half-life to days vs minutes for native GHRH
• Distinct from Mod GRF 1-29 — different half-life and pulse characteristics
• Typically combined with Ipamorelin as the standard GH protocol
• Regular IGF-1 monitoring recommended

CJC-1295 is most commonly prescribed as part of the CJC and Ipamorelin combination protocol. Our physicians will determine whether the DAC or non-DAC version is more appropriate for your protocol design. Book a consultation at /book.